Evaluation (Should Occur Concurrently with Intervention)
Key Points:
- Apart from history and examination (National Institute of Health Stroke Scale [NIHSS]) relevant to thrombolytic therapy, CT scan and glucose, other tests are not necessary before administering IV tPA. Obtaining them should not delay treatment.
- Review tPA indications/contraindications and document as to whether patient is eligible.
- Perform baseline NIHSS.
- Draw blood for lab tests.
- Perform EKG.
- Perform noncontrast head CT to exclude hemorrhage.
Review History and tPA Treatment Indications and Contraindications and Baseline NIHSS
Take a complete patient history, including a review of indications and contraindications for treatment with tPA [R].
The recommendations for treatment indications and contraindications were modified from the ICSI Technology Assessment Work Group for tPA for Acute Ischemic Stroke. They are based upon the National Institute of Neurologic Disorders and Stroke (NINDS) study recommendations with amendments to include recommendations from clinical practice at Mayo Clinic and treatment guidelines from the Stroke Treatment in the Community study [D].
See ICSI technology assessment Tissue-type Plasminogen Activator for Acute Ischemic Stroke (TA #28, 2005) for more information.
Indications for tPA
- Acute onset of focal neurological symptoms, consistent with ischemic stroke
- Clearly defined onset of stroke less than three hours prior to planned start of treatment; if the patient awakens with symptoms, onset is defined as the time of the last known baseline neurological status prior to retiring
- Eighteen years of age or older
- CT scan does not show evidence of intracranial hemorrhage, nonvascular lesions (e.g., brain tumor, abscess) or signs of advanced cerebral infarction such as sulcal edema, hemispheric swelling, or large areas of low attenuation consistent with extensive volume of infarcted tissue
- A patient with a seizure at the time of onset of stroke may be eligible for treatment as long as the physician is convinced that residual impairments are secondary to stroke and not a postictal phenomenon [R])
Contraindications for tPA
The clinical, history, laboratory, and radiological contraindications for thrombolytic therapy (tPA) that are listed below should be considered relative contraindications. Clinical judgment should weigh the patient's risk for receiving tPA compared with the benefits of thrombolytic therapy.
Clinical Contraindications
- Clearly defined onset of stroke greater than three hours prior to planned start of treatment; if the patient awakens with symptoms, onset is defined as the time of the last known baseline neurological status prior to retiring
- Rapidly improving symptoms
- Mild stroke symptoms/signs (NIHSS less than 4)
- Sensory symptoms only
- Ataxia without other deficits
- Dysarthria without other deficit
- Mild motor signs (non-disabling)
- Visual field defect without other deficit
- In the setting of middle cerebral artery (MCA) stroke, an obtunded or comatose state may be a relative contraindication.
- Clinical presentation suggestive of subarachnoid hemorrhage regardless of CT result
- Hypertension--systolic blood pressure (SBP) greater than 185 mm Hg or diastolic blood pressure (DBP) greater than 110 mm Hg
Patients with an SBP greater than 185 mm Hg or DBP greater than 110 mm Hg are excluded only if the blood pressure remains elevated on consecutive measurements, or if aggressive treatment is required to lower the blood pressure into an appropriate range.
Throughout this guideline, the work group frequently refers to blood pressure limits that are represented as systolic/diastolic. These ranges are intended to show the blood pressure limits as exceeding as either a given systolic level OR a given diastolic level.
History Contraindications
- Minor ischemic stroke within the last month
- Major ischemic stroke or head trauma within the last three months
- History of intracerebral or subarachnoid hemorrhage if recurrence risk is substantial
- Untreated cerebral aneurysm, arteriovenous malformation (AVM), or brain tumor
- Gastrointestinal or genitourinary hemorrhage within the last 21 days
- Arterial puncture at a noncompressible site within the last seven days or lumbar puncture within the last three days
- Major surgery or major trauma within the last 14 days
- Clinical presentation suggestive of acute myocardial infarction (MI) or post-MI pericarditis
- Patient taking oral anticoagulants and international normalized ratio (INR) greater than 1.7
- Patient receiving heparin within the last 48 hours and having an elevated activated partial thromboplastin time (aPTT)
- Patient receiving low-molecular-weight heparin within the last 24 hours
- Pregnant, or anticipated pregnant, female
- Known hereditary or acquired hemorrhagic diathesis or unsupported coagulation factor deficiency
Laboratory Contraindications
Glucose should always be measured prior to giving tPA; other parameters should be checked before treatment if there is reason to believe they may be abnormal (e.g., INR and aPTT should be checked if patient has been exposed recently to warfarin or heparin or if there is history of liver disease).
- Glucose less than 50 or greater than 400 mg/dL
- Platelet count less than 100,000/mm3
- INR greater than 1.7
- Elevated aPTT
- Positive pregnancy test
Radiology Contraindications
Once indications and contraindications have been reviewed, the patient should be appropriately managed and documentation of why tPA was given or not given must occur.
Baseline NIHSS
A history and neurological examination must be performed to assess whether the presentation is consistent with a stroke diagnosis and to estimate the severity of the deficit [R]. Use of the NIHSS by physicians and nursing staff is encouraged, as the scale provides a uniform method of evaluation to facilitate comparison between examiners during the early hours of the stroke care. The work group encourages use of the NIHSS as an initial evaluation tool and after resuscitation or treatment to assess for change.
The NIHSS is a quantitative measure of neurologic deficit in stroke patients that covers the key aspects of the neurological exam, including level of consciousness and orientation, eye movements, visual fields, facial weakness, motor strength in limbs, coordination, sensation, language and comprehension of language, articulation, and neglect. It can be performed in rapid fashion (five to eight minutes), which is an important feature in this clinical setting [R].
The NIHSS has been demonstrated in several evaluations to have both validity and reliability.
Refer to the original guideline document for more information on baseline NIHSS.
Perform Vital Signs Every 15 Minutes with Neuro Checks (Not NIHSS)
It is the standard of practice to perform a baseline NIHSS neurological assessment [R]. For subsequent neuro checks, a less extensive tool is appropriate. Performing a full NIHSS assessment every 15 minutes is often not feasible and may not be a good use of time. There is no evidence showing that performing a full NIHSS assessment every 15 minutes improves patient outcomes or improves the assessment and early detection of changes in patient condition. Unfortunately, there is not a standard validated non-NIHSS neurological assessment that is utilized by health care providers or that has been studied.
The work group has gathered the abbreviated neurological assessments used by several organizations and proposes the following non-NIHSS neuro check as an option.
Level of Consciousness – measures the level of alertness of the patient
- Is the patient alert, alert with stimulation or requires repeated stimulation to remain alert, or comatose?
- Is the patient able to correctly mouth his/her name and age?
- Is the patient able to correctly follow simple commands of opening and closing his/her eyes?
Motor Functions – measures the motor functions and patient's ability to follow commands
- Is the patient able to perform a series of arm movements?
- Is the patient able to perform a series of leg movements?
Language Skills – measures the amount of aphasia and dysarthria in response to asking patients to describe an item or read several sentences
See Appendix B in the original guideline document for examples of non-NIHSS neuro check forms.
The work group would like to encourage organizations to measure the use of non-NIHSS assessment tools to grow the evidence in this area.
Record Weight (estimate if needed)
Draw Blood for Lab Tests
Necessary/critical laboratory tests (results must be available before treatment in all cases):
- Glucose
- Prothrombin time (PT)/INR (if patient on warfarin)
Recommended laboratory tests (results must be available before treatment if physical exam and/or patient history indicates the possibility of abnormal results):
- Complete blood count (CBC) with platelet count
- Electrolytes, blood urea nitrogen (BUN), creatinine
- PT/INR, aPTT
Others to consider:
- Troponin
- Aspartate aminotransferase (AST)
These tests are used to evaluate for dehydration, metabolic disorders which might influence neurologic status (especially hypoglycemia and hyperglycemia), hematologic disorders such as polycythemia which may affect cerebral perfusion, or coagulopathies that could affect the treatment decision [R]. Prior to administration of tPA, the glucose level should be reviewed. If the patient is known to be on warfarin or has received heparin within the last 24 hours, the prothrombin time and partial thromboplastin time should be reviewed prior to treatment. A urine or serum pregnancy test should be obtained in women of childbearing potential if there is substantial reason to believe the patient may be pregnant.
Perform EKG
An EKG should be performed for the purpose of screening for concomitant cardiac disease, either acute or chronic, that may impact immediate treatment decisions.
Perform CT Head without Contrast
A CT scan without contrast must be performed prior to treatment with tPA, primarily for the purpose of excluding hemorrhage. Early signs of infarct should also be sought as this finding confers greater risk of symptomatic intracerebral hemorrhage with tPA treatment
[R]. It has been recently shown that MRI scans of the brain with diffusion- and susceptibility-weighted (gradient echo) sequences are much more sensitive than CT in detecting new infarction and chronic hemorrhage as well as of equal sensitivity for acute hemorrhage [C]. Consequently, when it is possible to perform MRI as quickly as CT with equally expert and timely interpretation, MRI may be used in this situation. Whichever is used, it is recommended that the greatest level of radiologic expertise possible be obtained for interpretation, with the caveat that this CT reading should not create excessive delays in the evaluation and treatment process. A process for rapid teleradiography CT readings should be organized and in place if needed to provide this expertise quickly.
Other Cardiac Assessment as Appropriate (Telemetry)
Consider if Intra-Arterial Thrombolytic Candidate
Intra-arterial thrombolytic therapy may be a treatment option for selected patients presenting in an early time frame but beyond the three-hour time window for intravenous tPA [R].
The availability of this option will be institution dependent, and patients must be highly selected. If considering this treatment option for a patient, a physician must explain to the patient and family that this is not standard of usual care and has substantial risk. Despite the limitations of available study data, in cases of more severe presentation with basilar artery or middle cerebral artery occlusion, intra-arterial thrombolytic treatment may be appropriate because the prognosis without treatment is poor.
If the patient is an appropriate candidate for this treatment, consideration should be given to immediate transfer to an institution offering this intervention. If an endovascular interventionist skilled in this technique is available to the hospital, the patient should be mobilized quickly.
Criteria for consideration of angiographic evaluation for intra-arterial treatment:
- Middle cerebral artery occlusion defined by:
- Symptom complex consistent with this vascular distribution:
- Contralateral hemiplegia and face weakness
- Contralateral hemisensory loss
- Aphasia if ischemia is on left, "neglect" if on right
- Commonly, contralateral homonymous visual field deficit, reduced level of arousal, eye deviation toward side of brain ischemia (away from side of weakness)
- Middle cerebral artery (MCA) "clot sign" on baseline pretreatment CT scan with appropriate clinical presentation
- CT angiogram, MRA or transcranial Doppler (TCD) demonstration of the occlusion with appropriate clinical presentation
Treatment should begin greater than three hours but less than six hours from onset of symptoms.
- Basilar artery occlusion defined by the following.
- Symptom complex consistent with this vascular distribution:
- Quadriparesis, sometimes with posturing bulbar dysfunction (dysarthria, dysphagia, dysphonia)
- Typically dysconjugate eye movement deficits
- Commonly, depressed level of arousal, respiratory abnormalities
- Hyperdense "clot sign" in basilar artery on pretreatment CT scan with appropriate clinical presentation
- CT angiogram, MRA or TCD demonstration of the occlusion with appropriate clinical presentation
Treatment should begin greater than three hours but less than 12 hours from onset of symptoms.
Refer to the original guideline document for emerging technologies and for information on studies investigating intra-arterial thrombolysis in patients with middle cerebral artery and basilar artery occlusion.